Expertise in
6
conditions

Michael Girschikofsky

Ordensklinikum Linz GmbH Elisabethinen
Linz, AT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
6
conditions
Ordensklinikum Linz GmbH Elisabethinen
Linz, AT 

Overview

Michael Girschikofsky practices practicing medicine in Linz, Austria.

Mr. Girschikofsky is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelomonocytic Leukemia (CMML), Histiocytosis, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

International Rare Histiocytic Disorders Registry (IRHDR)
International Rare Histiocytic Disorders Registry (IRHDR)
Enrollment Status: Recruiting
Publish Date: June 24, 2025
Intervention Type: Other
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

36 Total Publications

International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic Neoplasms.
International Expert Recommendations for the Diagnosis and Treatment of Malignant Histiocytic Neoplasms.
Journal: Blood
Published: January 07, 2026

Frequently Asked Questions about Michael Girschikofsky

Is Michael Girschikofsky a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Michael Girschikofsky is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael Girschikofsky participate in research or clinical trials?

Yes. Michael Girschikofsky has published 36 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Michael Girschikofsky's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Girschikofsky's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile